Verona Pharma

News

GSK says Nucala hits the target in new COPD trial

GSK's severe asthma therapy Nucala could find a new lease of life as a treatment for chronic obstructive pulmonary disease (COPD) after showing a clear benefit in a phase 3 trial.<

News

Verona’s first-in-class COPD drug ‘could transform market’

Verona Pharma has claimed FDA approval for its chronic obstructive pulmonary disease (COPD) drug ensifentrine, which has been tipped as a future blockbuster.

News

Verona cuts $400m loan deal as it preps COPD drug for market

Verona Pharma has agreed a new $400 million debt facility with Oxford Finance and Hercules Capital designed to help the company navigate the possible approval and launch o

News

Verona builds case for COPD drug ensifentrine as filing near...

Verona Pharma is looking odds on for a regulatory approval for its chronic obstructive pulmonary disease (COPD) therapy ensifentrine, after chalking up a second positive phase 3 trial.

News

Verona cues up filings for COPD drug after it aces phase 3 t...

UK-based Verona Pharma has scored a key win in a phase 3 trial of its chronic obstructive pulmonary disease (COPD) drug ensifentrine, setting up regulatory filings in the first half of next

News